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Abstract
Background: Although highly active antiretroviral therapy (HAART) has dramatically decreased HIV-related
morbidity and mortality, the associated costs, toxicities, and resistance risks make the potential delay of HAART
initiation an attractive goal. Suppression of herpes simplex virus type 2 (HSV-2) may be a novel strategy for
achieving this goal because HSV-2 is associated with clinically significant increases in HIV viral load, the primary
driver of HIV disease progression.
Methods/Design: The VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial is a multicentre,
randomized, fully blinded, clinical trial of twice daily valacyclovir 500 mg versus placebo for delaying the need for
initiating HAART among HIV-1, HSV-2 co-infected HAART-naïve adults. 480 participants from Canada, Brazil and
Argentina will undergo quarterly clinical follow-up until reaching the composite primary endpoint of having a CD4
+ T-cell count ≤ 350 cells/mm3 or initiation of HAART for any reason, whichever occurs first. The primary analysis
will use a proportional hazards model, stratified by site, to estimate the relative risk of progression to this endpoint
associated with valacyclovir. Secondary analyses will compare the rates of change in CD4 count, median log10 HIV
viral load, drug-related adverse events, frequency of HSV reactivations, rate of acyclovir-resistant HSV, and quality of
life between study arms.
Discussion: Although HIV treatment guidelines continue to evolve, with some authorities recommending earlier
HAART among asymptomatic individuals, the potential delay of HAART remains a clinically relevant goal for many.
If shown to be of benefit, implementation of the VALIDATE intervention will require careful consideration of both
individual patient-level and public health implications.
Trial Registration: Current Controlled Trials ISRCTN66756285
ClinicalTrials.gov NCT00860977
Background
Highly active antiretroviral therapy (HAART) has dra-
matically reduced morbidity and mortality related to
HIV-1 infection (herein referred to as ‘HIV’), transform-
ing an invariably fatal disease into a manageable, chronic
condition. Although debate continues as to the advan-
tages and disadvantages of earlier HAART initiation, the
cost, potential long and short-term toxicities, and risk of
developing drug-resistant HIV associated with daily, life-
long HAART would make the delay of HAART initia-
tion an attractive goal for many patients. Suppression of
herpes simplex virus (HSV)-2 co-infection may provide
a novel therapeutic strategy for achieving this goal. The
VALacyclovir In Delaying Antiretroviral Treatment
Entry (VALIDATE) trial has been designed to address
this question.
Recommendations for initiating HAART are based on
the natural history of HIV infection and clinical trials of
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HIV therapy. After acute infection there is an initial
profound drop in the CD4-positive T lymphocyte count
from levels of > 1000 cells/mm3 to roughly 700 cells/
mm3 six months later [1]. Patients then enter a generally
asymptomatic period characterized by a steady CD4
count decline of about 50-60 cells/mm3 per year,
although this varies according to the HIV RNA viral
load set point [2-5]. The risk of opportunistic infection
and mortality rises sharply at CD4 counts ≤ 200 cells/
mm3. Current guidelines therefore agree that HAART is
warranted when the CD4 count falls to 350 cells/mm3
in asymptomatic, non-pregnant adults; debate continues
on the role of earlier treatment initiation, with some but
not all guidelines recommending treatment at a thresh-
old of 500 cells/mm3 [6-9]. Once HAART is initiated,
treatment must be lifelong, because HIV cannot be
eradicated, and because treatment interruptions are
associated with increased rates of HIV-associated and
non-HIV-associated conditions [10].
HSV-2 is among the most common co-infections in
HIV, with a prevalence of 52-95%, [11-16] and several
important interactions have been observed between
these two viruses. First, HSV-2 is associated with
increased HIV acquisition and transmission, even in
asymptomatic individuals [17-27]. Recent trials of daily
acyclovir for HSV-2 suppression, however, did not show
a benefit on decreasing HIV acquisition or transmission
[28-30]. Persistence of HIV target cells in the genital
tract, suboptimal dosing and inadequate adherence may
have contributed to the negative results[31]. Second,
both symptomatic, clinical recurrences of HSV-2, and
asymptomatic shedding of HSV-2 have been clearly
associated with increased HIV levels in both genital
secretions and plasma[32-35]. Upregulation of HIV
replication by HSV gene products such as infected cell
protein (ICP)-0, ICP-4, ICP-27 and Us11, and stimula-
tion of the NF-Kappa B pathway may contribute to
these increases in HIV viral load [36-40]. Further, clini-
cal trials using both acyclovir and valacyclovir suppres-
sive therapy in co-infected individuals, including 20 men
who have sex with men (MSM) in Peru, 140 women in
Burkina Faso, and 67 women in Thailand have demon-
strated clinically significant, reciprocal decreases in HIV
RNA viral load of 0.33-0.53 log10[41-43].
The plasma HIV viral load, in turn, is the major pre-
dictor of CD4 cell decline and HIV disease progression,
and viral load strata that increase by about 0.5 log
copies/mL correlate with increased rates of CD4 decline
of roughly 10 cells/mm3/year [2-5]. It follows, then, that
HSV-2 suppressive therapy might delay HIV disease
progression in HAART-untreated individuals through its
effects on the HIV viral load. Indeed, a meta-analysis
from the pre-HAART era suggested that > 3200 mg per
day of acyclovir offered a significant survival benefit
(incidence rate ratio for mortality, 0.81, 95%CI 0.68-
0.96), although this effect was largely related to treat-
ment of active herpesvirus disease in individuals with
late-stage HIV/AIDS [44]. More recently, the multicen-
tre Partners in Prevention trial from Sub-Saharan Africa
has shown that acyclovir 400 mg twice daily was asso-
ciated with moderately decreased progression to the
composite endpoint of CD4 < 200 cells/mm3, HAART
initiation, or non-trauma related death (hazard ratio =
0.84, 95%CI 0.71-0.98) [45].
These results bolster interest in the VALIDATE trial,
which is addressing related but complementary issues.
First, given the conduct of the Partners trial in resource-
limited settings, it remains important to study the
impact of HSV-2 suppression in co-infected patients
from industrialized and middle-income countries. The
endpoint of the Partners trial represented a stage of dis-
ease that can be avoided in settings where the standard
of care is to offer HAART earlier; it is encouraging,
therefore, that an exploratory analysis from the Partners
trial demonstrated a delay in achieving CD4 < 350 cells/
mm3 from acyclovir as well (HR = 0.81, 95%CI 0.71-
0.93, p = 0.002). Further, rates of CD4 count decline
may be different in Sub-Saharan Africa due to the
effects of nutritional status, heightened levels of immune
activation (for example, as a result of co- or intercurrent
infections), and HIV clade [46-49]. The predominant
clades in Sub-Saharan Africa (A, D and C) differ from
those in most industrialized countries (B and some
others) and in South America (B but some F, C and
recombinants)[50,51]. In addition, it should be noted
that disease progression was a secondary endpoint of
the Partners trial, which was primarily designed to study
the impact of HSV-2 suppression on HIV transmission.
Finally, VALIDATE is employing valacyclovir instead of
acyclovir for HSV-2 suppression, and the dose of 500
mg twice daily has been demonstrated to achieve excel-
lent herpes suppression in clinical trials of HIV, HSV-2
co-infected adults [41,42]. Valacyclovir is the pro-drug
of acyclovir, and may offer advantages over acyclovir
owing to an improved bioavailability (54.5% versus 15-
30%) and lower pill burden[52].
Chronic suppressive therapy with valacyclovir is safe,
well-tolerated and already in widespread use to prevent
HSV outbreaks in those with frequent (five times a year
or more) clinical reactivation. However, up to 90% of
individuals with HSV-2 infection do not have any symp-
toms at all [53]. If HIV co-infected, such individuals
may benefit from HSV-2 suppressive therapy not only
through its effects on reducing herpes transmission and
herpes reactivation, [54-56] but also through its salutary
effects on HIV. The purpose of this multicentre, rando-
mized, placebo-controlled clinical trial is therefore to
answer the question, “Among adults co-infected with
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HIV and HSV-2 who are not using chronic suppressive
anti-HSV therapy and who are neither currently using
nor deemed to require HAART, can oral valacyclovir




The VALIDATE study is a multicentre, randomized,
placebo-controlled, fully blinded, clinical trial of twice
daily oral valacyclovir 500 mg versus placebo with the
goal of delaying the need for initiating HAART among
HIV, HSV-2 co-infected individuals who neither use nor
require HAART, and who have not used chronic sup-
pressive anti-HSV therapy for at least the 6 months
prior to study initiation.
Study Objectives
The primary objective of this trial is to compare the
time from enrolment to the primary endpoint of either
a CD4 cell count ≤ 350 cells/mm3 measured on two
consecutive occasions at least 1 month apart, or initia-
tion of HAART for any reason, between adults with
both stable untreated HIV and HSV-2 co-infection who
are randomized to valacyclovir compared to those ran-
domized to placebo.
Secondary objectives are as follows:
• To compare the annual rate of change in the abso-
lute CD4 cell count between study arms.
• To compare the annual rate of change in the CD4
cell count percentage between study arms.
• To compare the median log10 HIV viral load
between study arms.
• To compare the rate of drug-related adverse events
between study arms.
• To compare the median frequency of HSV reacti-
vations per year between study arms.
• To compare the rate of acyclovir-resistant HSV
between study arms.
• To compare quality of life between study arms.
A substudy will characterize plasma markers of
inflammation in this cohort of HAART-naive HIV-
infected patients and compare the levels of these mar-
kers between study arms.
Study Hypotheses
The primary hypothesis of the trial is that valacyclovir
500 mg orally twice daily will delay the time until
HAART is initiated among adults co-infected by stable
untreated HIV and HSV type 2 co-infection. The sec-
ondary hypotheses are that valacyclovir 500 mg orally
twice daily is associated with a slower rate of change in
both the absolute CD4 cell count and the CD4 cell
count percentage, a lower median log10 HIV viral load,
a similar rate of drug-related adverse events, a lower
frequency of HSV reactivations, a similar rate of acyclo-
vir-resistant HSV, and improvements in quality of life
compared with placebo.
Eligibility Criteria
Individuals will be eligible for the trial if they meet the
following inclusion criteria:
• adult (aged 18 years or older or as per Local/Pro-
vincial Guidelines)
• documented HIV-1 infection (determined by EIA
and Western blot)
• documented HSV-2 seropositivity (determined by
ELISA during screening; see below)
• no use of chronic anti-HSV therapy for the past
6 months, and not anticipated to require chronic
anti-HSV therapy during the study
• antiretroviral naïve (no more than 14 days of total
prior ARV exposure)
• CD4 count within the 400-900 cells/mm3 range
(inclusive) on two consecutive occasions, with at least
one measurement within 4 weeks of initiating trial
• does not meet recommendations for initiating ARV
therapy according to current guidelines [57,58]
Chronic anti-HSV therapy refers to the regular, daily
use of medications with anti-HSV activity (such as acy-
clovir, valacyclovir, famciclovir, ganciclovir, valganciclo-
vir, cidofovir, foscarnet). It does not refer to the episodic
use of short courses of these medications for treatment
of isolated HSV flares for a few days at a time.
The exclusion criteria for this study are as follows:
• pregnancy or actively planning to become pregnant
• receiving chemotherapy, chronic steroid therapy or
other immunomodulatory medications (e.g. inter-
feron, azathioprine, methotrexate, TNF-alpha
antagonists, etc.)
• Estimated creatinine clearance < 30 mL/min
• Other medical condition likely to cause death
within 24 months
• Enrolled in a therapeutic vaccine or immunother-
apy trial
• Enrolled in another trial investigating the impact of
another intervention on HIV disease progression
• HIV elite controller (EC), phenotypically defined
here as documented duration of HIV infection of ≥5
years, a persistent CD4 cell count ≥500 cells/mm3,
and a persistent plasma HIV viral load of < 1000
copies/mL in the absence of antiretroviral therapy
[3,59-61]
Tan et al. Trials 2010, 11:113
http://www.trialsjournal.com/content/11/1/113
Page 3 of 10
A stringent, empiric definition of the EC phenotype
will be used because previous reports have primarily
characterized ECs on the basis of genetic and immune
markers beyond the means of this study [3,59-61]. The
heterogeneity of CD4 counts and viral loads in ECs
implies that a more permissive definition may overlap
considerably with the general HIV-infected population
and risk introducing a selection bias.
Study setting
The VALIDATE trial will be conducted in industrialized/
middle-income country settings. The study will rando-
mize 480 participants, 240 in each arm. Participants will
be recruited from sites including clinical research sites of
the CIHR Canadian HIV Trials Network (CTN), the
Instituto de Pesquisa Clinica Evandro Chagas (IPEC)
HIV/AIDS Clinical Research Center of the Oswaldo Cruz
Foundation in Rio de Janeiro, Brazil, and the Hospital
Fernandez/Fundación Huesped in Buenos Aires, Argen-
tina. The CTN is a nationwide partnership established in
1990 of over 30 clinical trial sites across Canada, includ-
ing both university-affiliated and community-based HIV
clinics, with extensive experience in conducting HIV clin-
ical trials. Both the IPEC Centre in Rio and the Hospital
Fernandez and affiliated Fundación Huesped in Buenos
Aires are national reference centres for infectious disease
research, care and training, and are experienced leaders
in international HIV/AIDS clinical trials.
Treatment Groups
Participants in the intervention group will receive oral
valacyclovir 500 mg twice daily, the standard dose used
for HSV-2 suppression in HIV-infected individuals
[15,62]. Valacyclovir is safe and well tolerated, as evi-
denced by clinical trials, where side effects have been
reported at rates no different from those of placebo, and
clinical experience [54,55,63,64]. Individuals in the con-
trol arm will receive an odourless placebo tablet identi-
cal to valacyclovir in appearance and taste, to be taken
twice daily. Use of other anti-HSV medication (including
topical acyclovir) during the trial is prohibited, except
during treatment of herpes flares (described below).
Randomization and blinding methods
Randomization is stratified by site in permuted blocks of
variable size (4 and 6) using a computer-generated list of
random numbers. The CTN created and coordinated the
allocation sequence, and randomization is performed
through a secure website which ensures allocation conceal-
ment. All participants and study personnel (including
investigators, research coordinators, data analysts) will be
blinded to treatment allocation throughout the trial. Access
to the allocation code will be restricted to one study statis-
tician who will not perform the final study analyses.
Outcome Measures
The primary outcome is the time from baseline until
reaching the primary endpoint, a composite of either a
CD4 cell count ≤ 350 cells/mm3 measured on two conse-
cutive occasions at least 1 month apart, or initiation of
HAART for any reason, whichever occurs first. This end-
point was selected because reaching the treatment
threshold for initiating HAART is an important clinical
event signifying the need for lifelong therapy. The CD4
count of ≤ 350 cells/mm3 must be confirmed by a second
measurement to verify the CD4 count is within the treat-
ment range before initiating therapy. The primary end-
point also includes the initiation of HAART for any
reason, since patients who start HAART outside these
guidelines are also committed to lifelong therapy. This
group may include individuals who choose to start ther-
apy at earlier stages of disease (e.g. because of high viral
load set-point), and some who develop HIV-related com-
plications (e.g. tuberculosis) at higher CD4 cell counts,
among others. For example, women who initiate HAART
during pregnancy primarily for the prevention of
mother-to-child transmission of HIV, and hepatitis B co-
infected individuals who initiate HAART primarily for
the purposes of treating their hepatitis B infection, will
also be considered to have met the primary endpoint. It
was important not to restrict the primary endpoint to
initiation of HAART alone, since some patients may not
initiate HAART despite reaching treatment thresholds
for reasons including patient anxiety, concerns about
adherence, and lack of familiarity with guidelines[65].
HAART initiation guidelines are continuously under
evaluation, and HIV treatment guidelines may change.
However, a change will not threaten the integrity of the
study for a number of reasons. First, guidelines on
HAART initiation have recently been revised [6,9].
Recommendations to uniformly increase the treatment
threshold above 350 cells/mm3 in both industrialized
and middle-income settings based on definitive clinical
trial data are not anticipated during the course of the
trial. Second, as described above, the primary endpoint
of this study is a composite of not only meeting the cur-
rent CD4 threshold of 350 cells/mm3, but also the
initiation of HAART for any reason, whichever occurs
first. Finally, randomization in this trial will be stratified
by site to help account for variation in practice regard-
ing initiation of HAART across sites.
The secondary outcome measures to be compared
between the two treatment groups include:
• Annual rate of change in CD4 count, calculated as
the slope of participants’ CD4 count change/time
• Annual rate of change in the CD4 cell count per-
centage, calculated as the slope of the participants’
CD4 count percentage change over time
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• Log10 plasma HIV viral load at 12, 24 and 36
months of follow-up
• Treatment-emergent adverse events and laboratory
abnormalities (CBC, plasma creatinine)
• Frequency of episodes of symptomatic HSV reacti-
vation at any anatomic site
• Proportion of microbiologically confirmed flares of
HSV during the trial that are caused by laboratory-
confirmed acyclovir-resistant HSV
• Overall quality of life as measured by the MOS-
HIV questionnaire at each 6-monthly time point.
Duration of Study Participation
Study visits will occur every 3 months over 2 years of
participant accrual and 3 years of follow-up. Once
enrolled, participants will enter the follow-up period
during which they will be treated with either valacyclo-
vir or placebo, and undergo follow-up visits every
3 months. Follow-up for an individual participant will
continue until the end of the 5-year study period unless
the primary endpoint is reached first. This means that
all participants will be followed until the 5-year trial
ends, unless they reach a primary endpoint first.
Safety
Adverse events and serious adverse events will be assessed
at each study visit, graded on a 4-point scale (Division of
AIDS Table for Grading the Severity of Adult and Pedia-
tric Adverse Events), and assessed for their relationship to
the study medication/intervention. The Data Safety Moni-
toring Committee (DSMC) of the CIHR CTN will be
responsible for safety monitoring in this trial, and will also
conduct safety analyses based on serious adverse events
every 6 months, and ad hoc when necessary. The DSMC
consists of clinicians, biostatisticians and a community
member, from Canada and the United States.
Adherence Assessments
Adherence will be assessed at each visit through pill
counts and through a self-report questionnaire (modi-
fied from the ACTG Adherence Questionnaire) at each
visit [66,67]. In addition, urine samples will be collected
from all study participants at pre-planned visits, stored
at -80°C, and tested for acyclovir by mass spectrometry
[68] to obtain overall estimates of adherence or cross
over. Testing will be performed at the conclusion of the
trial to help maintain blinding.
Management of symptomatic herpes during the trial
If a clinical reactivation of herpes symptoms occurs dur-
ing the trial, participants are instructed to continue their
study drug, present for clinical assessment, have samples
taken to attempt microbiologic confirmation of the
diagnosis where resources permit, and consider optional
open-label treatment. Although participants in the treat-
ment arm may thus receive a total valacyclovir dose of
up to 3 g per day for 5 days, this quantity remains well
within the safe therapeutic window of this drug. Of
note, the occurrence of herpes flares in a study partici-
pant does not in itself unblind the study, because a
small proportion of individuals taking chronic suppres-
sive anti-HSV medications can experience herpes reacti-
vations. If HSV resistance is suspected, specimens will
be tested for acyclovir resistance using a plaque reduc-
tion assay [69].
Ethical approval
Ethical approval was obtained from the Research Ethics
Board of the primary study site, the University Health
Network (REB# 09-0587-B), prior to commencement of
study activities at any site. Each study site also obtained
approval from the local research ethics board prior to
initiation of the study at that site. The research is being
conducted in accordance with the Declaration of
Helsinki.
Sample Size Calculation
It is hypothesized that suppression of HSV-2 using vala-
cyclovir will increase the time until participants’ CD4
counts reach ≤ 350 cells/mm3 or initiate HAART from
the expected value of 2 years to 2.75 years (see justifica-
tion below). Participants will be recruited over 2 years
and followed over 3 years. Using a conservative estimate
that 25% of the sample will be lost to follow-up on aver-
age half way through the 3-year follow-up period, the
expected years of follow-up is 0.75 × 3 years + 0.25 ×
1.5 years = 2.625 years overall. In order to detect a dif-
ference of 0.75 years with a two-sided a = 0.0492
(adjusted for multiple analyses by the method of O’Brien
and Fleming) [70] and 80% power in a survival analysis,
240 individuals will be required in each study arm, or
480 participants overall [71].
The expected rate at which HIV disease would pro-
gress in HAART-untreated individuals was based on
both a retrospective review of patient charts and the
published literature. Among 142 patients with at least 3
CD4 counts before starting HAART, with baseline CD4
count > 400 cells/mm3 at the Toronto General Hospital
Immunodeficiency Clinic, the median time from first
presentation to reaching CD4 ≤ 350 cells/mm3 was 2.0
years (Raboud JM, Li M: personal communication). In
the subset with higher baseline CD4 counts (> 500 cells/
mm3), the median time was 2.5 years. Consistent with
these findings, a published retrospective observational
cohort study of 4268 HIV-infected individuals in the
United Kingdom with baseline CD4 counts > 500 cells/
mm3 also found the median time to until reaching CD4
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counts ≤ 350 cells/mm3 or initiation of antiretroviral
therapy was 2.5 years [72]. Both are consistent with the
generally accepted rate of CD4 count decline of 50-60
cells/mm3 per year [2,3].
Valacyclovir 500 mg twice daily is estimated to
decrease HIV plasma viral load by 0.5 log copies/mL. In
previous studies, the magnitude of increase in HIV viral
load associated with HSV-2 infection and the reciprocal
decrease with valacyclovir 500 mg twice daily therapy
was 0.33-0.53 log10 copies/mL [18,32,33,41,42]. Further,
the impact on HIV viral load was more pronounced
with time and in those with higher baseline CD4 counts.
The median baseline CD4 counts in these trials were
226 (IQR 145-389) and 446 cells/mm3 (IQR 334-628)
respectively [41,42]. Among persons with higher baseline
CD4 counts of 400-900 cells/mm3, valacyclovir is antici-
pated to reduce HIV viral load by about 0.5 log10
copies/mL. Data from large cohort studies of untreated
HIV infection that correlate HIV viral load set-points
with rates of CD4 cell decline [2,3] suggest that valacy-
clovir will attenuate the rate of CD4 count decline by 10
cells/mm3/year. Over the 3-5 years of follow-up in this
study, the treatment arm is thus expected to experience
an overall attenuation in CD4 count decline of 30-50
cells/mm3, roughly equivalent to the CD4 count decline
seen in 9 months. The sample size calculation is based
on a prolongation in the time until CD4 ≤ 350 or
HAART initiation from 2 to 2.75 years. The Kaplan-
Meier estimates of the proportion of ART-naïve patients
who experience a fall in CD4 count to ≤ 350 cells/mm3
or who start HAART in the UK study cited above are
consistent with these figures [72].
Nine months is a clinically important difference in the
time for HIV-infected patients to delay initiation of life-
long HAART. During this time, patients could avoid the
costs, toxicity risks, and resistance risks of ARVs.
Because typical HAART regimens can cost $1200 per
month compared with only $150 per month for valacy-
clovir, this strategy could result in an annual net savings
of nearly $10000 per patient based on medication costs
alone. Further, although the toxicity profile of current
ARVs is significantly better than in earlier years of the
HIV epidemic, long-term toxicities remain unknown
because most of the agents in current use were
approved within the last 5-10 years. The ARV resistance
risks to be avoided are also considerable; in clinical trials
evaluating efavirenz-based HAART regimens, the cur-
rent ‘gold standard’ for first-line ARV therapy, 30-70%
of the 15-20% patients experiencing virologic failure at
one year have evidence of resistance to the NNRTI class
of drugs, effectively eliminating the potential for using
standard agents in this class thereafter [73-77]. Delaying
HAART also provides time for patients to prepare psy-
chologically for starting HAART, which is an important
predictor of subsequent adherence [78,79]. Nine months
is also the time between 3 quarterly appointments,
allowing ample time for clinician and patient to prepare
for HAART. Finally, although there is theoretical risk of
developing drug-resistant HSV with chronic valacyclovir,
this risk is minimal even in immunocompromised
patients. Resistance rates have stayed stable at 5-6%
despite increasing population exposure to related drugs
over 2 decades, perhaps because it imposes a fitness
cost on the virus [15,80-83]. Resistant HSV is occasion-
ally seen in advanced HIV patients with persistent
lesions despite therapy, not in asymptomatic shedding.
For safety, those with frequent recurrences unresponsive
to therapy during the trial will have their viral isolates
tested for resistance.
Interim Analysis
A single interim efficacy analysis is planned when 50%
of the study endpoints have occurred; or at 3.5 years of
follow-up, whichever occurs first. The DSMC will be
asked to advise on early discontinuation of the trial at
this point if there is clear evidence of benefit or harm in
the treatment arm as defined below, using a two-sided
statistical significance threshold of 0.0054 and power of
80% [70]. This analysis will have sufficient power to
determine whether the intervention arm can expect a
prolongation of the primary outcome from 2 years to
3.42 years. Based on the modest impact of HSV-2 and
valacyclovir on HIV viral load, it is unlikely that such
clear evidence of benefit will be seen at this interim
analysis.
Primary Analysis
The primary outcome of the trial is the time from base-
line until reaching the primary endpoint, a composite of
either a CD4 cell count ≤ 350 cells/mm3 measured on
two consecutive occasions at least 1 month apart, or
initiation of HAART for any reason, whichever occurs
first. The primary analysis will be a proportional hazards
model, stratified by site, which will estimate the relative
risk of progression to this endpoint associated with vala-
cyclovir. Participants who do not reach either endpoint
will be censored at the date of last CD4 count. The pri-
mary analysis will be conducted at the conclusion of the
trial using the a = 0.0492 level of significance. This
significance level adjusts for one interim analysis of
the data according to the method of O’Brien and
Fleming [70].
Secondary Analyses
Random effects models will be used to compare the
annual rate of change in the absolute CD4 cell count,
the annual rate of change in the CD4 cell count percen-
tage, and the median log10 HIV viral load between study
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arms. The rate of drug-related adverse events per year of
follow-up, the number of episodes of HSV reactivations
per year occurring at any anatomic site, the proportion
of microbiologically confirmed flares of HSV during the
trial that are caused by laboratory-confirmed acyclovir-
resistant HSV, and the median overall quality of life
score [84] at each 6-monthly time point will be com-
pared between groups using Wilcoxon rank sum tests.
All analyses will be by intention to treat, meaning that
all participants will be analysed in the groups to which
they were randomized.
Efforts to ensure that the CD4 and other trial data are
well collected include biannual investigator meetings to
review study procedures, regular site monitoring visits,
and electronic data checks at the CTN National Data
Centre. Because the analyses on rates of change in CD4
will only include CD4 counts prior to HAART initiation,
the usual problem in HIV clinical trials of missing data
among patients doing poorly clinically and dropping out
of the trial is not anticipated to be an issue. Patients
doing poorly clinically will reach the primary outcome,
and it is only their CD4 counts before this time that will
be included in the analysis.
Subgroup Analyses
Three sets of subgroup analyses of the primary outcome
will be performed. First, analysis will be conducted
according to serological evidence of dual HSV-2 and
HSV-1 infection, compared with only HSV-2 infection.
These exploratory data will contribute to the emerging
literature on the prognostic significance of HSV-1 in
HIV co-infection [85]. Second, subgroup analyses will
also be performed to determine whether participants
with higher levels of adherence achieve greater benefits
than those with lower adherence, recognizing that such
associations may be partially driven by unmeasured con-
founders such as health-seeking behaviours. Third, sub-
group analyses will also be performed according to
country (Canada vs Brazil vs Argentina) since small dif-
ferences related to clinical practice patterns, gender mix,
clade or unknown factors may exist.
Discussion
Given that HSV-2 is known to increase HIV viral load,
that biological mechanisms of this interaction have been
identified, and that pharmacologic suppression of HSV-
2 has been shown to cause reciprocal decreases in HIV
viral load, the hypothesis underlying the VALIDATE
trial is that valacyclovir 500 mg twice daily may attenu-
ate HIV disease progression and delay the need for initi-
ating HAART in HIV-1, HSV-2 co-infected adults.
Some data further suggest that acyclovir and, by exten-
sion, related drugs like valacyclovir, may have direct
anti-HIV activity [86,87]. Some investigators have
already advocated for all HIV patients to be routinely
screened for HSV-2, with all co-infected individuals
being offered chronic suppressive therapy in the hopes
of attenuating rates of CD4 count decline [15]. Because
acyclovir and its pro-drugs are safe, well-tolerated, and
widely available, their use in this setting is realistic if
benefit can be shown. However, type-specific HSV sero-
logic testing is not yet routinely available, and anti-HSV
drugs add to pill burden and cost, so demonstration of
their effectiveness in randomized, controlled clinical
trials is necessary before recommending widespread use.
Although the Partners in Prevention trial recently
demonstrated that HSV-2 suppression with acyclovir
400 mg twice daily results in a modest decrease in HIV
disease progression in a cohort of co-infected adults in
Sub-Saharan Africa, [45] the VALIDATE trial will exam-
ine this question in industrialized and middle-income
countries where HIV clade, comorbid conditions, and
standards of HIV care differ. Further, the intervention in
the current trial is valacyclovir, the pro-drug of acyclo-
vir, which has improved bioavailability relative to acyclo-
vir [52].
It is recognized that HIV treatment guidelines are
continuously under evaluation. In the time since the
VALIDATE trial was designed, some panels have
recommended that HAART should be initiated earlier,
at the CD4 cell count threshold of 500 cells/mm3
instead of 350 cells/mm3 [6,9]. However, other guideline
panels reviewing the same data have not reached the
same conclusion, [7,8] suggesting there remains clinical
equipoise regarding the optimal timing for initiating
therapy.
This ongoing debate should not threaten the scientific
integrity of the VALIDATE study for several reasons.
First, the primary endpoint of this study was intention-
ally designed as a composite of not only meeting the
CD4 threshold of 350 cells/mm3, but also the initiation
of HAART for any reason, including patient or provider
preference for earlier treatment, whichever occurs first.
Second, randomization in this trial will be stratified by
site to ensure that variation in practice regarding initia-
tion of HAART across sites is distributed equally
between treatment arms. Importantly, because no defini-
tive clinical trial addressing the question of when to
start therapy at thresholds of 350 cells/mm3 or higher is
anticipated within the next several years, the primary
objective of the VALIDATE trial remains highly clini-
cally relevant. Even in an era when therapy has been
broadly recommended at a CD4 threshold of 350 cells/
mm3, the median CD4 count at treatment initiation in
industrialized countries has been 200-300 because of
costs, patient preference, and concerns about toxicities,
adherence and resistance. If shown to be beneficial,
HSV-2 suppression could thus offer important salutary
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effects to individuals deemed eligible for HAART in the
interim period while arrangements are made for medica-
tion coverage and while patients are counseled about the
risks and benefits of antiretroviral therapy.
A related concern is that delays in the time until
initiation of HAART could theoretically result in greater
population-level risks of onward HIV transmission
owing to increased population viral load. If demon-
strated to be effective, use of the VALIDATE interven-
tion will thus require careful consideration of its
broader implications, and physicians will need to bal-
ance the personal clinical priorities of their patients with
those of society at large. However, implementation of
the VALIDATE intervention would not preclude bol-
stering of other interventions to curb the spread of HIV
infection. Further mitigating this concern is the hypoth-
esis that HSV-2 suppression, if implemented using an
appropriate regimen and/or in appropriate populations,
could have meaningful effects on decreasing HIV trans-
mission, even if existing acyclovir-based clinical trials
have been unsuccessful thus far [88,89].
Valacyclovir for HSV-2 suppressive therapy is an
attractive potential intervention for patients with HIV-1,
HSV-2 co-infection at early stages of HIV disease, and
the VALIDATE trial is hypothesized to validate this
potential for clinical benefit.
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